The sponsors of seven products in the later stages of the EU evaluation process are due to appear this week before the European Medicine Agency’s key advisory panel, the CHMP, to address outstanding concerns the panel has regarding their applications. Additionally, two companies seeking to extend the indications of already marketed products will appear before the committee to address concerns relating to their requests.
The CHMP may to decide issue an opinion on whether two of the seven initial marketing authorization applications (MAAs) –...








